Evaluation of sFlt-1/PlGF Ratio ,OPG and sEng as Predictive Biomarkers in the Diagnosis and Treatment Evaluation of Preeclampsia

Sponsor
Ammar Jassim Abed
Study ID
NCT07349277
Status
Recruiting
Apply to this trial

Conditions

  • Gestational Hypertension
  • Hypertensive Disorders of Pregnancy
  • Preeclampsia

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 45 Years
Healthy Volunteers
Accepted

Study Details

his study investigates the effectiveness of three specific biological markers (biomarkers) in the blood-the sFlt-1/PlGF ratio, soluble endoglin (sEng), and osteoprotegerin (OPG)-to better diagnose and monitor preeclampsia. Preeclampsia is a serious pregnancy complication characterized by high blood pressure and potential organ damage that affects 2-8% of pregnancies worldwide

Key Dates

First listed
Jan 16, 2026
Start date
Oct 10, 2025
Status verified
Jan 2026
Primary completion
Jan 30, 2026
Completion
Apr 30, 2026

Study Design

Enrollment
120 participants (estimated)

Arms

  • Arm: Preeclampsia - No Antihypertensive Treatment
    This group includes pregnant women diagnosed with preeclampsia. Blood samples are collected at the time of diagnosis before starting any antihypertensive treatment. All participants will receive standard clinical care after sample collection. Samples will be processed, aliquoted, and stored at -80°C for biomarker analysis (sFlt-1, PlGF, soluble endoglin, and osteoprotegerin).
  • Arm: Preeclampsia - With Antihypertensive Treatment
    is group includes pregnant women diagnosed with preeclampsia who are receiving standard antihypertensive therapy as part of their clinical care. Blood samples (5 mL) will be collected for measurement of biomarkers (sFlt-1, PlGF, sEng, OPG). Samples will be processed, aliquoted, and stored at -80°C. Clinical parameters and treatment details will also be recorded for analysi
  • Arm: Healthy Pregnant Controls
    his group includes healthy pregnant women without preeclampsia. Blood samples (5 mL) will be collected to serve as controls for biomarker analysis. Samples will be processed, aliquoted, and stored at -80°C. Participants will receive routine prenatal care.

Primary Outcome Measure

Serum sFlt-1 concentration [ Time Frame: At enrollment (20-36 weeks of gestation) ]

Central Contacts

Related Studies